The promotion of continuous glucose monitoring (CGM) to standard of care for type 1 diabetes and insulin-treated type 2 diabetes reflects a robust and wide evidence base for the technology's effectiveness supported by real-world efficacy data. Multiple CGM devices are available worldwide and are marketed, in part, based on accuracy data. In this Viewpoint, we argue that accuracy metrics are no longer a point of difference between CGM devices as almost all exceed an acceptable threshold. We also argue that domains of standardisation, clinical outcomes, and sustainability should now be given primacy as CGM devices seek to be implemented for new indications. These domains are key for the success of the next generation of CGM devices. Additionally, we discuss the need to address inequalities in accessing clinically impactful technologies.

中文翻译：

---

连续血糖传感器精度：超越主要指标


将连续血糖监测 （CGM） 推广为 1 型糖尿病和胰岛素治疗的 2 型糖尿病的标准护理，反映了该技术有效性的强大而广泛的证据基础，并得到了真实世界疗效数据的支持。多种 CGM 设备在全球范围内可用，部分基于精度数据进行营销。在这个观点中，我们认为准确性指标不再是 CGM 设备之间的差异点，因为几乎所有设备都超过了可接受的阈值。我们还认为，随着 CGM 设备寻求针对新适应症实施，标准化、临床结果和可持续性领域现在应该放在首位。这些领域是下一代 CGM 设备成功的关键。此外，我们还讨论了解决获得具有临床影响力的技术方面的不平等问题的必要性。